Cancer Directory Forum is open to all those in the Cancer Community: from Patients to Professionals to Caregivers. Please be Compassionate and Respectful at all times.
Forum breadcrumbs - You are here:Cancer CommunityCancer Types: Bladder CancerHighlighting the Latest Advanceme …You need to log in to create posts and topics.Highlighting the Latest Advancements in Bladder Cancer
admin(@admin)24 PostsMay 2, 2019, 1:11 PMQuote from admin on May 2, 2019, 1:11 PMThomas W. Flaig, MD, professor and associate dean for clinical research, Genitourinary Cancer Program, Division of Medical Oncology, University of Colorado, discusses the most dramatic change in the treatment landscape for patients with advanced bladder cancer. Over the last several years, 5 checkpoint inhibitors have been approved in this space.
Checkpoint inhibitors are leading to response rates in the 20% to 25% range as monotherapy. Flaig says he would like to see higher response rates. Both patients and providers want durable responses that are well tolerated, and checkpoint inhibitors appear promising in that respect.
Clinical trials are looking at combining checkpoint inhibitors like PD-1/PD-L1 inhibitors with CTLA-4 inhibitors or chemotherapy. These trials provide hope of higher response rates with similar durability, Flaig concludes. Click link to watch video, https://www.targetedonc.com/videos/highlighting-the-latest-advancements-in-bladder-cancer
Thomas W. Flaig, MD, professor and associate dean for clinical research, Genitourinary Cancer Program, Division of Medical Oncology, University of Colorado, discusses the most dramatic change in the treatment landscape for patients with advanced bladder cancer. Over the last several years, 5 checkpoint inhibitors have been approved in this space.
Checkpoint inhibitors are leading to response rates in the 20% to 25% range as monotherapy. Flaig says he would like to see higher response rates. Both patients and providers want durable responses that are well tolerated, and checkpoint inhibitors appear promising in that respect.
Clinical trials are looking at combining checkpoint inhibitors like PD-1/PD-L1 inhibitors with CTLA-4 inhibitors or chemotherapy. These trials provide hope of higher response rates with similar durability, Flaig concludes. Click link to watch video, https://www.targetedonc.com/videos/highlighting-the-latest-advancements-in-bladder-cancer
Click for thumbs down.0Click for thumbs up.0Last edited on May 2, 2019, 1:11 PM by admin · #1
Highlighting the Latest Advancements in Bladder Cancer
Quote from admin on May 2, 2019, 1:11 PMThomas W. Flaig, MD, professor and associate dean for clinical research, Genitourinary Cancer Program, Division of Medical Oncology, University of Colorado, discusses the most dramatic change in the treatment landscape for patients with advanced bladder cancer. Over the last several years, 5 checkpoint inhibitors have been approved in this space.
Checkpoint inhibitors are leading to response rates in the 20% to 25% range as monotherapy. Flaig says he would like to see higher response rates. Both patients and providers want durable responses that are well tolerated, and checkpoint inhibitors appear promising in that respect.
Clinical trials are looking at combining checkpoint inhibitors like PD-1/PD-L1 inhibitors with CTLA-4 inhibitors or chemotherapy. These trials provide hope of higher response rates with similar durability, Flaig concludes. Click link to watch video, https://www.targetedonc.com/videos/highlighting-the-latest-advancements-in-bladder-cancer
Thomas W. Flaig, MD, professor and associate dean for clinical research, Genitourinary Cancer Program, Division of Medical Oncology, University of Colorado, discusses the most dramatic change in the treatment landscape for patients with advanced bladder cancer. Over the last several years, 5 checkpoint inhibitors have been approved in this space.
Checkpoint inhibitors are leading to response rates in the 20% to 25% range as monotherapy. Flaig says he would like to see higher response rates. Both patients and providers want durable responses that are well tolerated, and checkpoint inhibitors appear promising in that respect.
Clinical trials are looking at combining checkpoint inhibitors like PD-1/PD-L1 inhibitors with CTLA-4 inhibitors or chemotherapy. These trials provide hope of higher response rates with similar durability, Flaig concludes. Click link to watch video, https://www.targetedonc.com/videos/highlighting-the-latest-advancements-in-bladder-cancer